(Q43869761)

27 November 2017

title

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma (English)

1 reference

27 November 2017

1 reference

4

1 reference

27 November 2017

3

Charles S Fuchs

1 reference

27 November 2017

David P Ryan

1

1 reference

27 November 2017

Matthew H Kulke

2

1 reference

27 November 2017

Steven R Grossman

5

1 reference

27 November 2017

Jeffrey A Morgan

6

1 reference

27 November 2017

Craig C Earle

7

1 reference

27 November 2017

Ramesh Shivdasani

8

1 reference

27 November 2017

Haesook Kim

9

1 reference

27 November 2017

Robert J Mayer

10

1 reference

27 November 2017

Jeffrey W Clark

11

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

27 November 2017

1 reference

27 November 2017

volume

94

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

97-103

1 reference

27 November 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Pancreatic cancer: state-of-the-art care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Phase II study of gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Chemotherapy for advanced pancreatic cancer: it may no longer be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

inferred from DOI database lookup

7 January 2021

based on heuristic

A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

inferred from DOI database lookup

7 January 2021

based on heuristic

A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10202

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.10202

1 reference

27 November 2017

1 reference